

Summary of the risk management plan for Phenilzhar/Phenilic/Methylphenidate Generis 18, 27, 36 and 54 mg depottabletter (methylphenidate)

This is a summary of risk management plan (RMP) for Phenilzhar/Phenilic/Methylphenidate Generis 18, 27, 36 and 54 mg depottabletter. The RMP details important risks of Phenilzhar/Phenilic/Methylphenidate Generis 18, 27, 36 and 54 mg depottabletter, how these risks can be minimised, and how more information will be obtained about Phenilzhar/Phenilic/Methylphenidate Generis 18, 27, 36 and 54 mg depottabletter (missing information).

Phenilzhar/Phenilic/Methylphenidate Generis 18, 27, 36 and 54 mg depottabletter's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Phenilzhar/Phenilic/Methylphenidate Generis 18, 27, 36 and 54 mg depottabletter should be used.

Important new concerns or changes to the current ones will be included in updates of Phenilzhar/Phenilic/Methylphenidate Generis 18, 27, 36 and 54 mg depottabletter's RMP.

I. The medicine and what it is used for

Phenilzhar/Phenilic/Methylphenidate Generis 18, 27, 36 and 54 mg depottabletter is authorised for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) (see SmPC for the full indication). It contains methylphenidate as the active substance, and it is given by oral route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Phenilzhar/Phenilic/Methylphenidate Generis 18, 27, 36 and 54 mg depottabletter together with measures to minimise such risks are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation measures*.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Phenilzhar/Phenilic/Methylphenidate Generis 18, 27, 36 and 54 mg depottabletter is not yet available, it is listed under 'missing information' below.

11.A List of important risks and missing information

Important risks of Phenilzhar/Phenilic/Methylphenidate Generis 18, 27, 36 and 54 mg depottabletter are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Phenilzhar/Phenilic/Methylphenidate Generis 18, 27, 36 and 54 mg depottabletter. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risks and missing information	
Important Identified Risks	• Serious cardiovascular events • Reduced weight gain (pediatric indication only) • Decreased rate of growth (pediatric indication only)
Important Potential Risks	• Sexual maturation delayed (pediatric indication only)
Missing Information	• Long-term effects

11.B Summary of important risks

The safety information in the Product Information is aligned to the reference medicinal product.

11.C Post-authorisation development plan

11.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Phenilzhar/Phenilic/Methylphenidate Generis 18, 27, 36 and 54 mg depottabletter.

11.C.2 Other studies in post-authorisation development plan

There are no studies required for Phenilzhar/Phenilic/Methylphenidate Generis 18, 27, 36 and 54 mg depottabletter.